JPH0848619A - Skin cosmetic - Google Patents

Skin cosmetic

Info

Publication number
JPH0848619A
JPH0848619A JP20427294A JP20427294A JPH0848619A JP H0848619 A JPH0848619 A JP H0848619A JP 20427294 A JP20427294 A JP 20427294A JP 20427294 A JP20427294 A JP 20427294A JP H0848619 A JPH0848619 A JP H0848619A
Authority
JP
Japan
Prior art keywords
skin
cosmetic
effect
test
pigmentation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP20427294A
Other languages
Japanese (ja)
Inventor
Takashi Abe
隆 安部
Hajime Kikuchi
源 菊池
Hiroshi Togiya
啓 研谷
Toshio Hikima
俊雄 引間
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kanebo Ltd
Original Assignee
Kanebo Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kanebo Ltd filed Critical Kanebo Ltd
Priority to JP20427294A priority Critical patent/JPH0848619A/en
Publication of JPH0848619A publication Critical patent/JPH0848619A/en
Pending legal-status Critical Current

Links

Landscapes

  • Cosmetics (AREA)

Abstract

PURPOSE:To obtain a skin cosmetic excellent in the remedying effect for chapped and dried skin developed as skin aging goes, also in usability and presenting pigmentation-remedying effect, etc., containing, as active ingredient, methyl methionine sulfonium chloride. CONSTITUTION:This skin cosmetic contains pref. 0.05-5.0wt.%, based on the whole cosmetic, of methyl methionine sulfonium chloride of the formula, and can be made into a form of lotion, cream, milky lotion or pack. This cosmetic has significant chapped skin-remedying effect, being excellent in usability. Besides, this cosmetic has the suppressive effect against melanogenesis due to ultraviolet light and rapid fading effect for pigmentation, causing no onset of skin irritancy due to ultraviolet light, and also being good in preservability.

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【産業上の利用分野】本発明は、皮膚老化防止、ならび
に皮膚美白に優れた皮膚化粧料に関する。さらに詳しく
は、皮膚の老化に伴って生じる、荒れ肌および乾燥肌の
改善効果に優れ、さらに使用性にも優れた皮膚化粧料、
ならびに皮膚安全性に優れ、紫外線による皮膚の色素沈
着を改善する効果、色黒の皮膚を速やかに淡色化する効
果を有し、さらに保存安定性にも優れた皮膚化粧料に関
する。
BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a skin cosmetic excellent in preventing skin aging and whitening skin. More specifically, skin cosmetics that are excellent in the effect of improving rough skin and dry skin caused by aging of the skin, and are also excellent in usability,
The present invention also relates to a skin cosmetic having excellent skin safety, an effect of improving skin pigmentation due to ultraviolet rays, an effect of quickly lightening dark skin, and an excellent storage stability.

【0002】[0002]

【従来の技術および発明が解決しようとする課題】老化
皮膚とは、乾燥して滑らかさのない荒れ肌で、角質細胞
剥離現象が認められる皮膚である。そして、老化皮膚
は、ターンオーバー速度が遅く、また皮膚に老化防止効
果が付与発現するとターンオーバー速度が速くなると言
われている。
2. Description of the Related Art Aged skin is dry and non-smooth rough skin in which keratinocyte exfoliation phenomenon is observed. It is said that aging skin has a slow turnover speed, and that the turnover speed increases when the skin has an antiaging effect.

【0003】従来より、種々の老化防止剤を配合した皮
膚老化防止化粧料が市場に多くみられる。しかし、これ
らの皮膚老化防止化粧料は、一般に、老化防止等の効果
は遅効性で、長期間の連用後に始めて効果が現れるとい
うように、十分満足し得るものではなく、改良の余地を
残しているのが実情であった。
Conventionally, there are many skin anti-aging cosmetics containing various anti-aging agents in the market. However, these skin anti-aging cosmetics are generally slow in the effects of anti-aging and the like, and the effects appear only after continuous use for a long period of time, which is not sufficiently satisfactory and leaves room for improvement. It was the reality.

【0004】本発明者らは、このような実情に鑑み、従
来技術の難点を改良せんとして鋭意研究を重ねた結果、
メチルメチオニンスルホニウムクロリドを含有すること
を特徴とする皮膚化粧料が、老化によって生じた、荒れ
た皮膚の構造を緻密化し、亢進させることによって、荒
れ肌を早期に改善させ、さらに使用感の点でも優れるこ
とを見いだし、本発明の完成に到った。
In view of such circumstances, the inventors of the present invention have made earnest researches to improve the difficulties of the prior art, and as a result,
A skin cosmetic characterized by containing methylmethionine sulfonium chloride improves the rough skin early by densifying and promoting the structure of rough skin caused by aging, and is also excellent in terms of usability. As a result, the present invention has been completed.

【0005】一方、紫外線により皮膚は炎症(紅斑)を
起こし種々の因子が放出されメラノサイトを刺激する。
これにより色調は変化し黒化する。この黒化は、メラノ
サイトにおいて産生され表皮細胞に受け渡されるメラニ
ンの過剰生産が原因である。
On the other hand, the skin is inflamed (erythema) by ultraviolet rays and various factors are released to stimulate melanocytes.
As a result, the color tone changes and blackens. This blackening is due to the overproduction of melanin produced in melanocytes and delivered to epidermal cells.

【0006】従来より、皮膚の黒化やしみ、そばかすを
防ぎ本来の白い肌を保つために、L−アスコルビン酸を
始めとする、種々の美白剤を配合した美白化粧料が市場
に多くみられる。
[0006] Conventionally, whitening cosmetics containing various whitening agents such as L-ascorbic acid are often found in the market in order to prevent blackening, stains and freckles of the skin and maintain the original white skin. .

【0007】しかし、製剤中での保存安定性が不充分で
あったり、また紫外線による色素沈着改善効果および美
白効果が充分に認められないことが多い。この様に、色
素沈着改善効果、美白効果に優れ、かつ皮膚安全性が高
く、保存安定性に優れた美白化粧料を得ることは困難で
ある。
However, in many cases, the storage stability in the preparation is insufficient, and the effect of improving pigmentation and whitening effect by ultraviolet rays are not sufficiently observed in many cases. As described above, it is difficult to obtain a whitening cosmetic composition which is excellent in pigmentation improving effect and whitening effect, has high skin safety, and is excellent in storage stability.

【0008】本発明者らは、このような実情に鑑み、従
来技術の難点を改良せんとして鋭意研究を重ねた結果、
メチルメチオニンスルホニウムクロリドを含有すること
を特徴とする皮膚化粧料が、色素沈着改善効果、美白効
果に優れ、かつ皮膚安全性が高く、保存安定性に優れる
ことを見いだし、本発明の完成に到った。
[0008] In view of such circumstances, the inventors of the present invention have made earnest researches to improve the difficulties of the prior art, and as a result,
It was found that a skin cosmetic characterized by containing methylmethionine sulfonium chloride has a pigmentation improving effect, an excellent whitening effect, a high skin safety, and an excellent storage stability, and has completed the present invention. It was

【0009】本発明の皮膚化粧料の有効成分として使用
するメチルメチオニンスルホニウムクロリドは、消化性
潰瘍治療剤あるいは肝疾患治療剤として、医薬の分野で
利用されている。しかし、本化合物に関する老化防止作
用ならびに美白作用は全く知られていなかった。本化合
物の化学式はC6 14ClNO2 Sで表され、分子量は
199.70である。その性状は、白色の結晶または結
晶性の粉末で、わずかに特異の臭いと弱い塩味がある。
吸湿性で、水に極めて溶けやすく、氷酢酸またはギ酸に
溶けやすく、エタノール、エーテルにほとんど溶けな
い。融点は約140℃である。また、pH は4.0〜
5.0(5%水溶液)である。
Methylmethionine sulfonium chloride used as an active ingredient of the skin cosmetic of the present invention is used in the field of medicine as a therapeutic agent for peptic ulcer or liver disease. However, the antiaging effect and the whitening effect of this compound have not been known at all. The chemical formula of this compound is represented by C 6 H 14 ClNO 2 S, and its molecular weight is 199.70. Its appearance is white crystals or crystalline powder with a slight peculiar odor and a weak salty taste.
Hygroscopic, extremely soluble in water, easily soluble in glacial acetic acid or formic acid, almost insoluble in ethanol and ether. The melting point is about 140 ° C. Also, the pH is 4.0-
It is 5.0 (5% aqueous solution).

【0010】すなわち、本発明は、皮膚の老化に伴って
生じる、荒れ肌および乾燥肌の改善効果に優れ、さらに
使用性にも優れた皮膚化粧料を提供すること、ならびに
色素沈着改善効果、美白効果に優れ、かつ皮膚安全性が
高く、保存安定性に優れた皮膚化粧料を提供することを
目的とするものである。
That is, the present invention provides a skin cosmetic which is excellent in improving rough skin and dry skin caused by aging of the skin, and is also excellent in usability, and is effective in improving pigmentation and whitening effect. It is an object of the present invention to provide a skin cosmetic having excellent skin stability, high skin safety, and excellent storage stability.

【0011】[0011]

【課題を解決するための手段】上記の目的を達成するた
めに、本発明の皮膚化粧料は、つぎのような構成をと
る。すなわち、構造式化2
In order to achieve the above object, the skin cosmetic of the present invention has the following constitution. That is, structural formula 2

【化2】 で表されるメチルメチオニンスルホニウムクロリドを含
有することを特徴とする皮膚化粧料である。
Embedded image A skin cosmetic comprising a methylmethionine sulfonium chloride represented by:

【0012】メチルメチオニンスルホニウムクロリドの
本発明の皮膚化粧料中への配合量は、総量を基準とし
て、好ましくは、0.05〜5.0重量%である。
The amount of methylmethionine sulfonium chloride incorporated into the skin cosmetic of the present invention is preferably 0.05 to 5.0% by weight, based on the total amount.

【0013】本発明の皮膚化粧料は、常法に従って、ロ
ーション類、クリーム類、乳液類、パック類等の剤型に
することが可能である。
The skin cosmetic of the present invention can be formulated into lotions, creams, emulsions, packs and the like according to a conventional method.

【0014】なお、本発明の皮膚化粧料には、タール系
色素、酸化鉄などの着色顔料、パラベンなどの防腐剤、
脂肪酸セッケン、セチル硫酸ナトリウム、N−ステアロ
イル−L−グルタミン酸ナトリウムなどの陰イオン界面
活性剤、ポリオキシエチレンアルキルエーテル、ポリオ
キシエチレン脂肪酸エステル、ポリオキシエチレン多価
アルコール脂肪酸エステル、ポリオキシエチレン硬化ヒ
マシ油、多価アルコール脂肪酸エステル、ポリグリセリ
ン脂肪酸エステルなどの非イオン界面活性剤、テトラア
ルキルアンモニウム塩などの陽イオン界面活性剤、ベタ
イン型、スルホベタイン型、スルホアミノ酸型、などの
両性界面活性剤、レシチン、リゾフォスファチジルコリ
ンなどの天然系界面活性剤、酸化チタンなどの顔料、ジ
ブチルヒドロキシトルエンなどの抗酸化剤、キレート
剤、各種ビタミン、各種アミノ酸、各種動植物抽出エキ
スなどを、本発明の目的を達成する範囲内で適宜配合す
ることができる。
The skin cosmetic of the present invention includes a tar pigment, a coloring pigment such as iron oxide, a preservative such as paraben,
Anionic surfactants such as fatty acid soap, sodium cetyl sulfate, sodium N-stearoyl-L-glutamate, polyoxyethylene alkyl ether, polyoxyethylene fatty acid ester, polyoxyethylene polyhydric alcohol fatty acid ester, polyoxyethylene hydrogenated castor oil , Polyhydric alcohol fatty acid ester, nonionic surfactant such as polyglycerin fatty acid ester, cationic surfactant such as tetraalkylammonium salt, amphoteric surfactant such as betaine type, sulfobetaine type, sulfoamino acid type, lecithin , Natural surfactants such as lysophosphatidylcholine, pigments such as titanium oxide, antioxidants such as dibutylhydroxytoluene, chelating agents, various vitamins, various amino acids, various animal and plant extract extracts, etc. It can be appropriately blended within the range to achieve the target.

【0015】[0015]

【実施例】以下、実施例および比較例に基づいて本発明
を詳細に説明する。なお、本発明はこれらに限定される
ものではない。また、実施例および比較例で用いる%と
は重量%を意味する。
EXAMPLES The present invention will be described in detail below based on examples and comparative examples. The present invention is not limited to these. In addition,% used in Examples and Comparative Examples means% by weight.

【0016】また、本発明において使用した、(1)荒
れ肌実用試験、(2)官能試験(使用感)、(3)チロ
シナーゼ活性阻害試験、(4)皮膚色明度回復試験、
(5)美白実用試験、(6)光パッチ試験、(7)保存
安定性試験の各試験法は以下の通りである。
Further, used in the present invention, (1) rough skin practical test, (2) sensory test (feeling of use), (3) tyrosinase activity inhibition test, (4) skin color lightness recovery test,
The test methods of (5) whitening practical test, (6) optical patch test, and (7) storage stability test are as follows.

【0017】(1)荒れ肌実用試験 荒れ肌、乾燥肌を訴える女子パネラー(25〜50歳)
各群20名を対象にして、その顔面に実施例ないし比較
例を1日2回連続1ケ月塗布した。なお、評価は「荒れ
肌が改善された」と回答した人数で示した。
(1) Practical test for rough skin Female panelists (25 to 50 years old) who complain of rough and dry skin
Twenty people in each group were applied to the face with the Examples or Comparative Examples twice a day continuously for one month. The evaluation was shown by the number of people who answered that "rough skin was improved".

【0018】(2)官能試験(使用感) 各群パネラー20名が実施例と比較例とを10日間顔面
に連用した後の特性を評価した。評価は、親和性に関す
るアンケート項目に対し、「親和性が良い」と回答した
人数で示した。
(2) Sensory test (feeling of use) 20 panelists from each group evaluated the characteristics after continuously using the example and the comparative example for 10 days on the face. The evaluation is shown by the number of respondents who answered “Affinity is good” to the questionnaire items regarding affinity.

【0019】(3)チロシナーゼ活性阻害試験 マックルベイン緩衝液(pH6.8)1mlに0.3mg/
ml濃度のチロシン溶液に各濃度の試料溶液を加え、37
℃にて10分間の予備保温を行った。これに1mg/ml濃
度のチロシナーゼ(シグマ社製)0.1mlを加え37℃
にて15分間加温した後、分光光度計を用いて、波長4
75nmにて吸光度(A)を測定した。一方、チロシナー
ゼの代わりに緩衝液0.1mlを加えたものの吸光度
(B)、試料溶液の代わりに緩衝液0.1ml加えたもの
の吸光度(C)、更に試料溶液とチロシナーゼの代わり
に緩衝液0.2ml加えたものの吸光度(D)をそれぞれ
測定して、下式に従い阻害率(%)を算出した。
(3) Tyrosinase activity inhibition test 0.3 mg / ml in McClubain buffer (pH 6.8)
Add the sample solution of each concentration to the tyrosine solution of ml concentration, and
Preliminary incubation was performed at 10 ° C for 10 minutes. To this was added 0.1 ml of 1 mg / ml tyrosinase (Sigma) and 37 ° C.
After heating for 15 minutes at 4 ° C using a spectrophotometer,
Absorbance (A) was measured at 75 nm. On the other hand, the absorbance (B) of 0.1 ml of buffer solution added in place of tyrosinase, the absorbance (C) of 0.1 ml of buffer solution in place of the sample solution, and the buffer solution 0.1% in place of sample solution and tyrosinase. The absorbance (D) of 2 ml was measured, and the inhibition rate (%) was calculated according to the following formula.

【0020】 阻害率(%)=〔1−(A−B)/(C−D)〕×100Inhibition rate (%) = [1- (AB) / (CD)] × 100

【0021】(4)皮膚色明度回復試験 被験者20名の左右上腕内側部皮膚にUVA、UVB領
域の紫外線の最小紅斑量を3日間連続照射した。照射終
了後、実施例塗布部と比較例塗布部皮膚の基準明度(V
0 値、V0 ’値)を測定した。引き続いて、実施例およ
び比較例を照射部位に1日3回ずつ4週間連続で塗布し
た。照射開始1、2、4週間後に実施例塗布部と比較例
塗布部皮膚の皮膚明度(Vn 値、Vn ’値)を測定し
て、表1の判定基準によって皮膚色の回復評価を行っ
た。
(4) Skin color lightness recovery test The skin of the left and right upper arms of 20 subjects was irradiated with the minimum erythema dose of UV rays in the UVA and UVB regions for 3 days. After the irradiation, the reference lightness (V
0 value, V0 'value) was measured. Subsequently, the examples and comparative examples were applied to the irradiation site three times a day for four consecutive weeks. 1, 2, and 4 weeks after the start of irradiation, the skin lightness (Vn value, Vn 'value) of the skin of the application part of the invention and the skin of the application part of the comparative example was measured, and the recovery of the skin color was evaluated according to the criteria shown in Table 1.

【0022】なお、皮膚の明度(マンセル表示系V値)
は、高速分光色彩計で測定して得られたX、Y、Z値よ
り算出した。また、評価は被験者20名の4週間後の評
価点の平均値で示した。
The brightness of the skin (V value of Munsell display system)
Was calculated from X, Y, and Z values obtained by measurement with a high-speed spectrocolorimeter. The evaluation was shown by the average value of the evaluation points of 20 subjects after 4 weeks.

【0023】[0023]

【表1】 [Table 1]

【0024】(5)美白実用試験 夏期の太陽光に3時間(1日1.5時間で2日間)曝さ
れた被験者20名の前腕屈側部皮膚を対象として、左右
前腕屈側部皮膚には太陽光に曝された日より実施例と比
較例とを朝夕1回ずつ8週連続塗布した。
(5) Practical Whitening Test A forearm flexion side skin of 20 subjects exposed to sunlight in summer for 3 hours (1.5 hours a day for 2 days) was applied to the left and right forearm flexion side skin. From the day of exposure to sunlight, the example and the comparative example were applied once in the morning and in the evening for eight consecutive weeks.

【0025】なお、評価は、比較例塗布部より実施例塗
布部の皮膚淡色化効果が強いことが確認された被験者の
人数で示した。
The evaluation was shown by the number of subjects for whom it was confirmed that the skin lightening effect of the application part of the example was stronger than that of the application part of the comparative example.

【0026】(6)光パッチ試験 被験者25名の前腕屈側部皮膚に試料0.05g を塗布
した直径1.0cmのパッチテスト用絆創膏を用いて24
時間クローズドパッチを行った。パッチ除去後、夏期の
太陽光に1時間(1日の合計)曝露させた。
(6) Optical patch test Twenty-five subjects were tested with a patch test plaster of 1.0 cm in diameter, which was prepared by applying 0.05 g of the sample to the skin on the flexion side of the forearm.
Timed closed patch. After removal of the patch, it was exposed to summer sunlight for 1 hour (1 day total).

【0027】評価は無塗布部と比較し、皮膚反応(紅
斑、浮腫等)が強い場合を光パッチ試験陽性とした。判
定結果は陽性を示した人数で表した。
In the evaluation, the photopatch test was positive when the skin reaction (erythema, edema, etc.) was strong as compared with the non-coated part. The determination result was represented by the number of people who showed positive results.

【0028】(7)保存安定性試験法 試料を45℃の恒温槽に入れて経日観察を行い、表2の
判定基準に従って評価した。なお、「異常」とは、変色
・変臭が生じる、化粧水で沈殿が生じる、乳化物で相分
離が生じる現象を意味する。
(7) Storage stability test method The sample was placed in a thermostatic chamber at 45 ° C. and observed over time, and evaluated according to the criteria shown in Table 2. The term "abnormal" means a phenomenon in which discoloration or odor occurs, precipitation occurs in lotion, and phase separation occurs in an emulsion.

【0029】[0029]

【表2】 [Table 2]

【0030】実施例1〜2、比較例1〔ローション〕 (処方)Examples 1 and 2, Comparative Example 1 [lotion] (prescription)

【0031】[0031]

【表3】 [Table 3]

【0032】(調製法)表3に記載のA成分およびB成
分を均一に溶解した後、A成分にB成分を均一に混合攪
拌分散し、製品とした。
(Preparation method) After the components A and B shown in Table 3 were uniformly dissolved, the component B was uniformly mixed with the component A with stirring and dispersion to obtain a product.

【0033】実施例3〜4、比較例2〔スキンクリー
ム〕 (組成)
Examples 3 to 4 and Comparative Example 2 [skin cream] (composition)

【0034】[0034]

【表4】 [Table 4]

【0035】(調製法)表4に記載のA成分およびB成
分を均一に加熱溶解して温度を80℃にした。ついで、
A成分中に、B成分を注入乳化した後、攪拌しながら3
0℃まで冷却した。
(Preparation method) The components A and B shown in Table 4 were uniformly heated and dissolved to bring the temperature to 80 ° C. Then,
After injecting and emulsifying the B component in the A component, stir 3
Cooled to 0 ° C.

【0036】実施例1〜4および比較例1〜2につい
て、前記荒れ肌試験および官能試験を実施した。その結
果を表5に示す。
The rough skin test and the sensory test were carried out on Examples 1 to 4 and Comparative Examples 1 and 2. The results are shown in Table 5.

【0037】[0037]

【表5】 [Table 5]

【0038】表5に示した通り、各実施例は荒れ肌改善
効果および使用感に優れていることは、明らかである。
As shown in Table 5, it is clear that each example is excellent in the rough skin improving effect and the feeling of use.

【0039】試験例1(チロシナーゼ活性阻害試験) 本法で測定したメチルメチオニンスルホニウムクロリド
のチロシナーゼ活性阻害率を、表6に示す。
Test Example 1 (Tyrosinase activity inhibition test) Table 6 shows the tyrosinase activity inhibition rate of methylmethionine sulfonium chloride measured by this method.

【0040】[0040]

【表6】 [Table 6]

【0041】表6より、メチルメチオニンスルホニウム
クロリドには、抗チロシナーゼ作用があることを見いだ
した。
From Table 6, it was found that methylmethionine sulfonium chloride has an anti-tyrosinase action.

【0042】実施例1〜4および比較例1〜2につい
て、前記皮膚明度回復試験、美白実用試験、光パッチ試
験および保存安定性試験を実施した。その結果を表7に
示す。
With respect to Examples 1 to 4 and Comparative Examples 1 and 2, the skin lightness recovery test, the whitening practical test, the optical patch test and the storage stability test were carried out. The results are shown in Table 7.

【0043】[0043]

【表7】 [Table 7]

【0044】表7に示した通り、実施例1〜2のローシ
ョンは、諸試験の全てにおいて顕著な結果を示した。ま
た、実施例3〜4のスキンクリームも同様に、諸試験の
全てにおいて顕著な結果を示した。
As shown in Table 7, the lotions of Examples 1 and 2 showed remarkable results in all the tests. Similarly, the skin creams of Examples 3 to 4 also showed remarkable results in all the tests.

【0045】[0045]

【発明の効果】以上記載の如く、本発明は、顕著な荒れ
肌改善効果を有し、使用感の優れた有用な皮膚化粧料を
提供し、さらに紫外線による皮膚のメラニン色素の産生
抑制効果、皮膚の色素沈着の速やかな淡色化効果を有
し、紫外線による皮膚刺激の発症も無く、保存安定性の
高い優れた皮膚化粧料を提供することは明らかである。
Industrial Applicability As described above, the present invention provides a useful skin cosmetic having a remarkable rough skin improving effect and an excellent feeling of use, and further, an effect of suppressing the production of melanin pigment in the skin by ultraviolet rays, a skin It is clear that it provides an excellent skin cosmetic which has a rapid lightening effect of pigmentation, does not cause skin irritation due to ultraviolet rays, and has high storage stability.

フロントページの続き (72)発明者 引間 俊雄 神奈川県小田原市寿町5丁目3番28号 鐘 紡株式会社化粧品研究所内Front page continuation (72) Inventor Toshio Hikima 5-3 28, Kotobuki-cho, Odawara-shi, Kanagawa Kanebo Co., Ltd.

Claims (1)

【特許請求の範囲】[Claims] 【請求項1】 下記構造式 【化1】 で表されるメチルメチオニンスルホニウムクロリドを含
有することを特徴とする皮膚化粧料。
1. The following structural formula: A skin cosmetic comprising a methylmethionine sulfonium chloride represented by:
JP20427294A 1994-08-05 1994-08-05 Skin cosmetic Pending JPH0848619A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP20427294A JPH0848619A (en) 1994-08-05 1994-08-05 Skin cosmetic

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP20427294A JPH0848619A (en) 1994-08-05 1994-08-05 Skin cosmetic

Publications (1)

Publication Number Publication Date
JPH0848619A true JPH0848619A (en) 1996-02-20

Family

ID=16487734

Family Applications (1)

Application Number Title Priority Date Filing Date
JP20427294A Pending JPH0848619A (en) 1994-08-05 1994-08-05 Skin cosmetic

Country Status (1)

Country Link
JP (1) JPH0848619A (en)

Similar Documents

Publication Publication Date Title
JP3638832B2 (en) Cosmetic and / or dermatological composition comprising at least one mulberry extract, at least one seaweed extract and at least one salicylic acid derivative
JPS6251608A (en) Improved moisture rising lotion
JP2000229834A (en) Cosmetics
JPH03153609A (en) Skin-beautifying cosmetic
JP2986262B2 (en) Whitening cosmetics
JPH1179951A (en) Tyrosinase activity promoter
WO1998052516A1 (en) Scalp care compositions
JPH1112117A (en) Cosmetic composition or pharmaceutical composition
JP2001131031A (en) Composition for scalp and hair
JPH0859452A (en) Skin cosmetics
JPS6270309A (en) Skin beautifying cosmetic
JPH08291039A (en) Skin-lightening cosmetic
JP3083105B2 (en) Cosmetics
JP2002114629A (en) Cosmetic
JP3649889B2 (en) Whitening cosmetics
CN109745262B (en) Composition for whitening spot-fading face cream
JPH0848619A (en) Skin cosmetic
JP2000026269A (en) Cosmetic
JPH1017431A (en) Skin ununiformity improver and cosmetic containing the same
KR100364314B1 (en) Use of unfermented honey as a depigmenting agent
JP2002121110A (en) Cosmetic
JPS6023307A (en) Skin beautifying cosmetic
JP3023249B2 (en) Whitening cosmetics
JP2002114700A (en) Melanocyte activator
JPH06271454A (en) Skin cosmetic